Practical DiabetesAltman Publishing, 2006 - 210 pages Focusing on the areas of maximum anxiety for the junior doctor this handbook covers the management of the patient whether in a clinic or emergency department of a hospital. The book is set out in a problem oriented way to aid diagnosis and treatment. |
From inside the book
Results 6-10 of 13
Page 197
Sorry, this page's content is restricted.
Sorry, this page's content is restricted.
Page 204
... diabetic foot ulceration 100-1 , 102-3 diabetic ketoacidosis and hyperosmolar hyperglycaemic state 31 necrotising fasciitis osteomyelitis 104 105 urinary tract infection 99 anticonvulsants 146-7 antidepressants 146 anti - obesity agents ...
... diabetic foot ulceration 100-1 , 102-3 diabetic ketoacidosis and hyperosmolar hyperglycaemic state 31 necrotising fasciitis osteomyelitis 104 105 urinary tract infection 99 anticonvulsants 146-7 antidepressants 146 anti - obesity agents ...
Page 205
... diabetic ketoacidosis see ketoacidosis , diabetic diagnosis 7-10 dialysis 132 diet hypertension management interventions 192 in lipid management 182-3 diltiazem 169 162 dipeptidyl peptidase ( DPP - IV ) inhibitors 94 diuretics thiazide ...
... diabetic ketoacidosis see ketoacidosis , diabetic diagnosis 7-10 dialysis 132 diet hypertension management interventions 192 in lipid management 182-3 diltiazem 169 162 dipeptidyl peptidase ( DPP - IV ) inhibitors 94 diuretics thiazide ...
Page 206
... diabetic ketoacidosis distinction 22 enteral feeding 47-8 fasting 65-6 follow - up of emergency 31-4 stroke 46 hyperglycaemic emergencies see ketoacidosis , diabetic ; hyperosmolar hyperglycaemic state ( HHS ) hyperkalaemia , in ACE ...
... diabetic ketoacidosis distinction 22 enteral feeding 47-8 fasting 65-6 follow - up of emergency 31-4 stroke 46 hyperglycaemic emergencies see ketoacidosis , diabetic ; hyperosmolar hyperglycaemic state ( HHS ) hyperkalaemia , in ACE ...
Page 207
... diabetic ketoacidosis and hyperosmolarhyperglycaemic state 29-30 perioperative 72-3 prescribing 55 steroid - induced diabetes timing of administration type 2 diabetes 90-2 48 55 see also continuous subcutaneous insulin infusion ( CSII ) ...
... diabetic ketoacidosis and hyperosmolarhyperglycaemic state 29-30 perioperative 72-3 prescribing 55 steroid - induced diabetes timing of administration type 2 diabetes 90-2 48 55 see also continuous subcutaneous insulin infusion ( CSII ) ...
Contents
Classification and diagnosis | 1 |
The metabolic syndrome | 13 |
Hyperglycaemic emergencies and hypoglycaemia | 21 |
Acute general medicine and diabetes | 41 |
Insulin therapy in type 1 diabetes | 51 |
Perioperative management | 69 |
Management of type 2 diabetes | 75 |
Infections in diabetes | 95 |
Diabetic eye disease | 107 |
Diabetic renal disease | 117 |
Neuropathy | 135 |
Hypertension | 157 |
Lipids | 175 |
The management of type 2 diabetes in primary care Dr M Grenville | 191 |
Sources and websites | 201 |
Other editions - View all
Common terms and phrases
abnormal ACE inhibitor acid acidosis acute agents angiotensin antibiotics antihypertensive associated atorvastatin autonomic neuropathy basal-bolus regimen bedtime benefit blocker blood glucose levels blood pressure cardiovascular cartridges Chapter clinical combination common creatinine diabetic nephropathy diabetic patients diagnosis disease dose drugs dyslipidaemia effect especially fasting glucose fatty fibrates foot glitazones glycaemic control haemorrhages HbA1c HDL cholesterol hyperkalaemia hypertension hypoglycaemia improved increased risk infection insulin infusion insulin resistance insulin treatment isophane ketoacidosis lipid liver long-acting analogue lower meal measurements ment metabolic syndrome metformin mg daily microalbuminuria microvascular complications mmol/L myocardial infarction non-diabetic normal obese occurs oedema OHAS osteomyelitis peripheral pioglitazone prefilled primary progression proteinuria RCTs reduce renal failure renal function renal impairment retinal risk factors Sanofi-Aventis screening serum creatinine side-effects significant statins stents sulphonylurea symptoms target tests therapy trial triglycerides type 2 diabetes type 2 patients UKPDS ulceration usually vascular